Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    June 2018
  1. FOTOPOULOU C, Sehouli J, Mahner S, Harter P, et al
    HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
    Ann Oncol. 2018 Jun 4. pii: 5032848. doi: 10.1093.
    PubMed     Text format    


    May 2018
  2. MIRZA MR, Pignata S, Ledermann JA
    Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Ann Oncol. 2018 May 10. pii: 4994787. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  3. RAY-COQUARD I, Morice P, Lorusso D, Prat J, et al
    Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 Apr 25. pii: 4983953. doi: 10.1093.
    PubMed     Text format    


    February 2018
  4. PICCIRILLO MC, Scambia G, Bologna A, Signoriello S, et al
    Quality of life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2018 Feb 16. pii: 4864364. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. OSKAY-OZCELIK G, Alavi S, Richter R, Keller M, et al
    EXPRESSION III: Patient s Expectations and Preferences regarding Physician-Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries.
    Ann Oncol. 2018 Feb 5. pii: 4838337. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. BANERJEE S, Oza AM, Birrer MJ, Hamilton EP, et al
    Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Ann Oncol. 2018 Feb 1. pii: 4833235. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  7. FRIEDLANDER M, Rau J, Lee CK, Meier W, et al
    Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenan
    Ann Oncol. 2017 Dec 18. pii: 4756055. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  8. PROVENCHER DM, Gallagher CJ, Parulekar WR, Ledermann JA, et al
    OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
    Ann Oncol. 2017 Nov 23. pii: 4654091. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. LEDERMANN JA
    Front-line therapy of advanced ovarian cancer: new approaches.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  10. MONK BJ, Chan JK
    Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  11. MARTH C, Reimer D, Zeimet AG
    Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  12. BOOKMAN MA, Okamoto A, Stuart G, Yanaihara N, et al
    Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  13. BRAND AH, DiSilvestro PA, Sehouli J, Berek JS, et al
    Cytoreductive surgery for ovarian cancer: quality assessment.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  14. CHRISTIE EL, Bowtell DDL
    Acquired chemotherapy resistance in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  15. ODUNSI K
    Immunotherapy in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  16. EISENHAUER EA
    Real-world evidence in the treatment of ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  17. PUJADE-LAURAINE E
    New treatments in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  18. PIGNATA S, C Cecere S, Du Bois A, Harter P, et al
    Treatment of recurrent ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


  19. PARK SB, Kwok JB, Asher R, Lee CK, et al
    Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
    Ann Oncol. 2017;28:2733-2740.
    PubMed     Text format     Abstract available


  20. DUSKA LR, Kohn EC
    The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


    September 2017
  21. LORUSSO D, Pignata S
    Role of adjuvant chemotherapy in early stage endometrioid and clear cell ovarian cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  22. OSELEDCHYK A, Leitao MM Jr, Konner J, O'Cearbhaill RE, et al
    Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  23. RONCOLATO FT, Gibbs E, Lee CK, Asher R, et al
    Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.
    Ann Oncol. 2017 Jun 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  24. CONDORELLI R, Andre F
    Combining PI3K and PARP inhibitors for breast and ovarian cancer tratement.
    Ann Oncol. 2017 May 15. doi: 10.1093.
    PubMed     Text format    


  25. BAMIAS A, Gibbs E, Khoon Lee C, Davies L, et al
    Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
    Ann Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017;28:996-1004.
    PubMed     Text format     Abstract available


    April 2017
  27. CHIANNILKULCHAI N, Pautier P, Genestie C, Bats AS, et al
    Networking for ovarian rare tumors: a significant breakthrough improving disease management.
    Ann Oncol. 2017 Apr 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. RAY-COQUARD I, Lorusso D
    Immunotherapy and Epithelial Ovarian Cancer: a double-edged sword?
    Ann Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format    


    March 2017
  29. POVEDA A, Del Campo JM, Ray-Coquard I, Alexandre J, et al
    Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  30. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. KARAM A, Ledermann JA, Kim JW, Sehouli J, et al
    Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2017
  32. MCGEE J, Bookman M, Harter P, Marth C, et al
    5th Ovarian Cancer Consensus Conference: Individualized Therapy and Patient Factors.
    Ann Oncol. 2017 Jan 24. pii: mdx010. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  33. WILSON MK, Pujade-Lauraine E, Aoki D, Mirza MR, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  34. LEARY AF, Quinn M, Fujiwara K, Coleman RL, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): Clinical trial design for rare ovarian tumours.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  35. MATULONIS UA, Wulf GM, Barry WT, Birrer M, et al
    Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw672. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2016
  36. MESNAGE SJ, Auguste A, Genestie C, Dunant A, et al
    Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  37. LIU JF, Moore KN, Birrer MJ, Berlin S, et al
    Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
    Ann Oncol. 2016;27:2124-2130.
    PubMed     Text format     Abstract available


  38. WEIDERPASS E, Botteri E
    Ovarian cancer mortality trends: which factors are involved?
    Ann Oncol. 2016;27:1977-1978.
    PubMed     Text format    


  39. MANGILI G, Sigismondi C, Lorusso D, Cormio G, et al
    The role of staging and adjuvant chemotherapy in stage I Malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  40. LEDERMANN JA, Sessa C, Colombo N
    appendix 7: Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies).
    Ann Oncol. 2016;27.
    PubMed     Text format    


  41. PALUCH-SHIMON S, Cardoso F, Sessa C, Balmana J, et al
    Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
    Ann Oncol. 2016;27.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: